Semaglutide Aids Significant Weight Loss for Lung Transplant Eligibility

Obesity presents a significant challenge for patients awaiting lung transplant, often leading to complications and even disqualification from the transplant list due to elevated surgical risks and poorer post-operative outcomes. Current strategies for pre-transplant weight management, such as diet and exercise, are often insufficient or too slow for patients with rapidly progressing end-stage lung disease. This case report addresses the critical need for effective and safe pharmacological interventions to achieve rapid and substantial weight loss in obese lung transplant candidates.

Over the 8-month treatment period, the patient demonstrated remarkable progress. Her body weight decreased significantly from 100 kg to 76 kg, resulting in a total weight loss of 24 kg. This translates to a substantial 24% reduction in her initial body weight. Her BMI improved dramatically from 38 kg/m² to 29 kg/m², bringing her within the acceptable range for lung transplant consideration. The most critical finding was that the patient successfully achieved the necessary weight loss criteria, enabling her to be reactivated on the lung transplant list within 8 months of initiating Semaglutide therapy. Furthermore, the patient reported improved exercise tolerance and a reduction in obesity-related comorbidities, with no significant adverse events reported throughout the treatment duration.